Search results
Showing 16 to 30 of 517 results for syndrome
Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)
Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]
Awaiting development [GID-TA10662] Expected publication date: TBC
Digitally enabled therapy for chronic tic disorders and Tourette Syndrome
In development [GID-MT605] Expected publication date: 19 December 2024
Evidence-based recommendations on continuous positive airway pressure for treating obstructive sleep apnoea/hypopnoea syndrome in adults.
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.
Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
In development [GID-TA11154] Expected publication date: TBC
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.
This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS114Show all sections
We are listening to your views on this Interventional procedures guidance. Comments close 23 April 2024.
This quality standard covers the management of colorectal (bowel) cancer in adults. It includes managing local disease and secondary tumours (metastatic disease). It describes high-quality care in priority areas for improvement.
View quality statements for QS20Show all sections
Sections for QS20
- Quality statements
- Quality statement 1: Testing for Lynch syndrome
- Quality statement 2: Discussion about treatment options for early rectal cancer
- Quality statement 3: Testing to guide systemic anti-cancer treatment
- Quality statement 4: Follow-up for detecting local recurrence and distant metastases
- Update information
- About this quality standard
All NICE products on irritable bowel syndrome. Includes any guidance, advice and quality standards.
This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.
Show all sections
Sections for NG217
- Overview
- 1 Diagnosis and assessment of epilepsy
- 2 Information and support
- 3 Referral to tertiary specialist services
- 4 Principles of treatment, safety, monitoring and withdrawal
- 5 Treating epileptic seizures in children, young people and adults
- 6 Treating childhood-onset epilepsies
- 7 Treating status epilepticus, repeated or cluster seizures, and prolonged seizures
This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and secondary tumours (metastatic disease).